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ABSTRACT
Cases of food poisoning with botulinum toxin have been reported as far back as Roman times. Emperor Leo VI 
of Byzantium prohibited the manufacturing of blood sausages with a law due to cases attributed to poisoning with 
Atropa belladonna. It was later proven that atropine does not have the effects described in the cases during his 
reign. It was not until the 19th century that scientists began detailed studies of the rising number of cases in which 
the patients reported nausea, vomiting, relaxation of muscles and inability to breathe properly. Such “outbreaks” of 
cases were reported in southern Germany and Belgium in short succession, which led medical scientists to believe 
they were connected. The toxin was first identified by Justinus Kerner - a German medical officer in Wuertemberg, 
as “ fatty acids” or “ fat toxin”. He failed to point the source of the toxin, however, he recognized the potential for 
medical use. Later in the 19th century Emile Pierre van Ermengem, a Belgian scientist, successfully identified the 
source of the “ fatty acids”. It was later called Botulinum toxin after the Latin word for sausages “botulus”. Since 
then this substance, produced by C. botulinum, has been studied in detail by scientists around the world and many 
uses have been found. It is utilized in the treatment of neurological conditions, posttraumatic conditions, muscle 
spasms, irregular sweating, chronic pain, skin wrinkles, etc. The military have found use for it as well - the potency 
of the toxin can be effectively used in closed environments. 
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WHAT IS THE BOTULINUM TOXIN? 
Botulinum toxin is produced by the bacterium 
Clostridium botulinum. It is among the most poison-
ous substances currently known to man. 
The structure of botulinum toxin type A consists 
of dual polypeptide chains (heavy 100 kda and light 
50 kda) connected via disulfide bond. The toxin is 
secreted from the bacterium as a single chain, then it 
is activated when divided into two chains by its own 
protease enzyme. The heavy chain is responsible for 
the attachment of the toxin to the target cell and the 
light is the active factor, blocking the release of neu-
rotransmitter (acetylcholine) (5).
There are seven subtypes of botulinum toxin cur-
rently known to scientists - type A, B, C, D, e, F and 
G. Only type A botulinum toxin has received ap-
proval for medical use by the US Federal Drug Ad-
ministration so far (7).
Intoxication occurs as a result of either ingesting 
the toxin in spoilt food or it getting into the blood-
stream through a wound. The lethal dose for hu-
mans is estimated to be 1.3-2.1 ng/kg intravenously, 
10-13 ng/kg if inhaled and 1000 ng/kg when ingested 
through the mouth.
The condition, caused by intoxication with bot-
ulinum toxin is known as botulism. The symptoms 
include high temperature, nausea, relaxation of fa-
cial muscles (mask-like facial expression), inability 
to breathe and lack of muscle strength in general (8).
In infants, C. botulinum can grow inside the intes-
tinal tract, producing botulinum toxin and can poi-
son the patient. This condition is known as “floppy 
baby syndrome”. In severe cases, the toxin can block 
parts of the respiratory system or the heart, which re-
sults in death. The syndrome can be mistaken with 
other conditions such as Guillain-Barre syndrome, 
myasthenia gravis, and stroke. Tests like brain scan-
ning and spinal fluid examination can help in diag-
nosing the correct condition. With proper diagnos-
ing and treatment the damage to the nerves heals 
within weeks to several months (9).
Exposure to low temperatures (below 3°C) slows 
down the growth of C. botulinum. The bacterium is 
also susceptible to high oxygen, high salt, and acidic 
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bacteria responsible for its production - Clostridium 
botulinum. It is an anaerobic, rod-shaped spore-
forming bacterium, producing one of the most potent 
neurotoxic substances known to man (3).
20th Century
In the beginning of the 20th century Carl Meier, a 
veterinarian working in San Francisco (USA) devel-
oped methods both for growing and eliminating C. 
botulinum. The results from his research were used 
in the fast developing canning industry in the USA 
at that time.
WWII
After the beginning of World War II the United 
States Army searched for ways to weaponize the bot-
ulinum toxin. Fort Detrick became the base for re-
search and a research team, headed by Carl Laman-
na and James Duff, (4) was formed. They developed 
a method for concentrating and crystalizing botuli-
num toxin, which was later used by Eduard Shantz 
for commercial production of cosmetic products.
Modern Day Use
During the late 1960s Scott, an ophthalmolog-
ic surgeon in San Francisco, who developed a tech-
nique for precision injection of ocular muscles, talk-
ed to Shantz. The reason for Scott’s interest in Shanz’s 
research was another doctor’s (Daniel Drachmann) 
successful attempt at paralyzing a chicken’s legs. 
Scott considered the toxin used in those experiments 
as a viable injectable agent against eye muscle spastic-
ity (Drachman, 1971; Scott, 2004).
Scott experimented on monkeys’ muscles with 
different substances, including alcohol, enzyme 
pH. The botulinum toxin is destroyed by heat (cook-
ing at more than 85°C for more than five minutes). 
The spores that produce the toxin are heat-resistant 
and will survive at around 100°C for extended peri-
ods of time.
Currently there are two types of botulinum anti-
toxins available. Trivalent (A, B, E) botulinum anti-
toxin is derived from animal sources (equines) using 
antibodies. The other substance is heptavalent (A, B, 
C, D, E, F, G) botulinum antitoxin, which is from the 
same source, but modified to be less immunogenic 
(6). 
DISCOVERY
Botulinum toxin was discovered in 1820 by Justi-
nus Kerner (1,2) in Germany after a series of food 
poisoning cases with similar symptomatic complex. 
The name of the toxin was given from the Latin term 
botulus, which means sausage, since all the cases 
were reported as food poisoning from eating sausag-
es. After numerous experiments, conducted on ani-
mals and on himself, Kerner concluded that the new 
toxin blocks the transmission of motor neuron sig-
nals without inhibiting sensory signals. However, the 
blockage was temporary and the severity was pro-
portional to the amount of poisonous food ingested. 
He therefore concluded that botulinum toxin might 
have medicinal use (2).
Emile Pierre van Ermengem also conducted a 
research on this new toxin and in 1895 identified the 
J. Kerner, painting by A. Bruckmann 
Emile Pierre van Ermengem
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blockers, snake neurotoxins. He tried botulinum 
toxin as well, intrigued by Drachmann’s discovery. 
Scott noted that a very small quantity of the toxin 
(picograms) induced prolonged paralysis in the tar-
get muscles alone, without any noticeable side effects 
(15).
Human experiments on healthy volunteers, as 
well as strabismus patients, began in the late 1970s. 
(16) The success of this new treatment method lead 
to the approval of the toxin by the FDA under the 
name of “Oculinum” (1989), which was later changed 
to Botox+ (17).
Since late 1980s and early 90s botulinum tox-
in type A (Botox) has successfully been used for the 
treatment of the following conditions:
• skin wrinkles such as crow’s feet, for example 
(11)
• high upper lip smile
• horizontal wrinkles on the forehead
• conditions caused by facial and neck muscle 
spasticity: blepharospasm, strabismus, dysto-
nia, spasmic dysphonia, achalasia, etc. (10)
• muscle spasticity after stroke, after brain or 
spinal cord injuries (14)
• involuntary contraction of the bladder mus-
cles and anal sphincter (which can lead to the 
exacerbation of anal fissures)
• excessive armpit sweating with unknown 
cause (13)
• migraines pain (2000 William Binder) (12)
• lower limb spasticity in pediatric patients 2 
years and older
Economics
Since 2018, botulinum toxin injections have been 
the most widely spread cosmetic operations. Medical 
personnel, authorized for the performance of such 
operation, varies by countries and includes plastic 
surgeons, aesthetic spa physicians, dermatologists, 
dentists, nurses etc.
The market for botulinum toxin products, used 
for cosmetic applications, was expected to reach ap-
proximately $3 billion by 2018.
Bioterrorism
The toxin, produced by C. botulinum can poten-
tially by used in terrorist attacks. This is due to the 
fact, that it can be absorbed through the eyes, mu-
cous membranes, non-intact skin and respiratory 
tract (19).
18th century – the first documented endemic outbreaks of food-borne botulism called ‘‘sausage poisoning’’  
in Europe
1817–1822 Justinus Kerner and botulinum toxin: Preliminary animal experiments, systematic descriptions of its clinical effects; theoretical considerations of its possible therapeutic use
1895–1897 Emile Pierre van Ermengem: Discovery of the neurotoxin-producing pathogen Clostridium botulinum
1910 J. Leuchs: Discovery of a second serologically distinct botulinum toxin serotype (type B)
1920–1930 H. Sommer: Purification of botulinum toxin
1946 C. Lamanna and J. Duff: Techniques of toxin concentration and crystallization
1949 A. Burgen: Description of the toxin’s action on acetylcholine release at the neuromuscular junction
1970s Description of wound and infant botulism
1941–1972 Edward Schantz: Production of a batch of toxin at Fort Detrick (USA)
1968 Contact between Alan Scott and Edward Schantz; search for therapeutic agents (e.g. botulinum toxin) to relax eye muscles
1973 Alan Scott: Publication of animal experiments with injections of botulinum toxin into eye muscles
1977–1980 Alan Scott: Treatment of strabismus patients with botulinum toxin; first publications of applica-tion in humans
1989 Approval of Alan Scott’s type A toxin batch as ‘‘Oculinum’’ in the USA; later named ‘‘Botox’’
1881–1988 Development of a type A toxin preparation in the UK; later called ‘‘Dysport’’
1990s Discovery of the molecular action of botulinum toxin (Schiavo, Montecucco, Dolly)
2000–2001 Approval of a therapeutic type B preparation in the USA and Europe (Myobloc, Neurobloc)
2005 Approval of a type A preparation in Germany (Xeomin)
Table 1. Historical steps in the discovery and development of botulinum toxin
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A Japanese terrorist group produced botuli-
num toxin and used it as aerosol in downtown To-
kyo during a 1990s terrorist attack, but fortunately 
caused no fatalities (20).
As far as detection is concerned, current NBC de-
tection equipment (ICAM or detection paper) will 
not test positive when used to test botulinum tox-
in-containing samples. To confirm the presence of 
botulinum toxin in the human body, the toxin can 
be quantitated by immunoassay of human biological 
fluids.
PRECAUTIONS
With all the opportunities for treatment botuli-
num toxin A provides, precautions must be taken be-
cause of all the possible side effects:
• temporary localized paralysis (1 week to 4 
months after toxin application)
• difficulty swallowing after application of bot-
ulinum toxin in the neck area
• fever and nausea
• headache
• allergic reactions
• bruising at the injection site; it is not a di-
rect side effect of the botulinum toxin itself, 
but rather the way of injecting it; it is recom-
mended to apply pressure to the injection site; 
if bruising occurs, it will most often last 7-11 
days 
• unwanted effects from therapeutic use are 
much more diverse than those from cosmetic 
use; they can vary both in time and intensity 
and be more dangerous to the patient’s health; 
they can occur as a result of critical muscle pa-
ralysis and include heart attack, arrhythmia, 
seizures, respiratory arrest, and death.
Usually, botulinum toxin can be administered 
into the wrong muscle group or spread from the in-
jection site, thus temporarily paralyzing adjacent 
muscles or muscle groups.
It is important to strictly follow the dosage proto-
col and to apply it after proper training and knowl-
edge of use is acquired.
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